{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:02:00Z","timestamp":1794002520498,"version":"4.8.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12325-025-03228-1","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T05:25:33Z","timestamp":1748409933000},"page":"3141-3157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Guideline-Recommended Disease-Modifying Therapies for Patients with Cardiorenal Disease: A Call-to-Action Narrative Review"],"prefix":"10.1007","volume":"42","author":[{"given":"Christoph","family":"Wanner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpesh N.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"De Nicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaster M.","family":"Allum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unai","family":"Aranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Seon","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"issue":"5","key":"3228_CR1","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","volume":"96","author":"KJ Jager","year":"2019","unstructured":"Jager KJ, Kovesdy C, Langham R, et al. A single number for advocacy and communication\u2014worldwide more than 850\u00a0million individuals have kidney diseases. Kidney Int. 2019;96(5):1048\u201350. https:\/\/doi.org\/10.1016\/j.kint.2019.07.012.","journal-title":"Kidney Int"},{"key":"3228_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102615","volume":"72","author":"S Chadban","year":"2024","unstructured":"Chadban S, Arici M, Power A, et al. Projecting the economic burden of chronic kidney disease at the patient level (Inside CKD): a microsimulation modelling study. EClinicalMedicine. 2024;72:102615. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102615.","journal-title":"EClinicalMedicine"},{"key":"3228_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102614","volume":"72","author":"GM Chertow","year":"2024","unstructured":"Chertow GM, Correa-Rotter R, Eckardt KU, et al. Projecting the clinical burden of chronic kidney disease at the patient level (Inside CKD): a microsimulation modelling study. EClinicalMedicine. 2024;72:102614. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102614.","journal-title":"EClinicalMedicine"},{"issue":"10159","key":"3228_CR4","doi-asserted-by":"publisher","first-page":"P2052","DOI":"10.1016\/S0140-6736(18)31694-5","volume":"392","author":"KJ Foreman","year":"2018","unstructured":"Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016\u201340 for 195 countries and territories. Lancet. 2018;392(10159):P2052\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(18)31694-5.","journal-title":"Lancet"},{"issue":"1","key":"3228_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12955-020-01559-x","volume":"18","author":"JT Cooper","year":"2020","unstructured":"Cooper JT, Lloyd A, Sanchez JJG, et al. Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review. Health Qual Life Outcomes. 2020;18(1):310. https:\/\/doi.org\/10.1186\/s12955-020-01559-x.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"3228_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230512","volume":"15","author":"S Elshahat","year":"2020","unstructured":"Elshahat S, Cockwell P, Maxwell AP, et al. The impact of chronic kidney disease on developed countries from a health economics perspective: a systematic scoping review. PLoS One. 2020;15(3):e0230512. https:\/\/doi.org\/10.1371\/journal.pone.0230512.","journal-title":"PLoS One"},{"issue":"4S","key":"3228_CR7","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","journal-title":"Kidney Int"},{"issue":"2","key":"3228_CR8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ekir.2017.11.003","volume":"3","author":"KA Betts","year":"2018","unstructured":"Betts KA, Woolley JM, Mu F, et al. The cost of hyperkalemia in the United States. Kidney Int Rep. 2018;3(2):385\u201393. https:\/\/doi.org\/10.1016\/j.ekir.2017.11.003.","journal-title":"Kidney Int Rep"},{"issue":"5S","key":"3228_CR9","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5S):S1\u2013127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008.","journal-title":"Kidney Int"},{"issue":"12","key":"3228_CR10","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075\u201390. https:\/\/doi.org\/10.2337\/dci22-0027.","journal-title":"Diabetes Care"},{"issue":"2","key":"3228_CR11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.ekir.2020.11.039","volume":"6","author":"B Stengel","year":"2021","unstructured":"Stengel B, Muenz D, Tu C, et al. Adherence to the kidney disease: improving global outcomes CKD guideline in nephrology practice across countries. Kidney Int Rep. 2021;6(2):437\u201348. https:\/\/doi.org\/10.1016\/j.ekir.2020.11.039.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"3228_CR12","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.kint.2023.12.003","volume":"105","author":"VA Luyckx","year":"2024","unstructured":"Luyckx VA, Tuttle KR, Abdellatif D, et al. Mind the gap in kidney care: translating what we know into what we do. Kidney Int. 2024;105(3):406\u201317. https:\/\/doi.org\/10.1016\/j.kint.2023.12.003.","journal-title":"Kidney Int"},{"issue":"3","key":"3228_CR13","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.amepre.2017.02.015","volume":"53","author":"SH Dharmarajan","year":"2017","unstructured":"Dharmarajan SH, Bragg-Gresham JL, Morgenstern H, et al. State-level awareness of chronic kidney disease in the U.S. Am J Prev Med. 2017;53(3):300\u20137. https:\/\/doi.org\/10.1016\/j.amepre.2017.02.015.","journal-title":"Am J Prev Med"},{"issue":"5","key":"3228_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067386","volume":"13","author":"N Tangri","year":"2023","unstructured":"Tangri N, Moriyama T, Schneider MP, et al. Prevalence of undiagnosed stage\u00a03 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study. BMJ Open. 2023;13(5):e067386. https:\/\/doi.org\/10.1136\/bmjopen-2022-067386.","journal-title":"BMJ Open"},{"issue":"4","key":"3228_CR15","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ekir.2018.04.004","volume":"3","author":"M Smith","year":"2018","unstructured":"Smith M, Herrington WG, Weldegiorgis M, et al. Change in albuminuria and risk of renal and cardiovascular outcomes: natural variation should be taken into account. Kidney Int Rep. 2018;3(4):939\u201349. https:\/\/doi.org\/10.1016\/j.ekir.2018.04.004.","journal-title":"Kidney Int Rep"},{"issue":"2","key":"3228_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030131","volume":"13","author":"JI Barzilay","year":"2024","unstructured":"Barzilay JI, Farag YMK, Durthaler J. Albuminuria: an underappreciated risk factor for cardiovascular disease. J Am Heart Assoc. 2024;13(2):e030131. https:\/\/doi.org\/10.1161\/JAHA.123.030131.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"3228_CR17","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1007\/s12325-023-02482-5","volume":"40","author":"N Tangri","year":"2023","unstructured":"Tangri N, Peach EJ, Franzen S, Barone S, Kushner PR. Patient management and clinical outcomes associated with a recorded diagnosis of stage\u00a03 chronic kidney disease: the REVEAL-CKD study. Adv Ther. 2023;40(6):2869\u201385. https:\/\/doi.org\/10.1007\/s12325-023-02482-5.","journal-title":"Adv Ther"},{"issue":"9","key":"3228_CR18","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/j.ekir.2022.05.033","volume":"7","author":"G James","year":"2022","unstructured":"James G, Garcia Sanchez JJ, Carrero JJ, et al. Low adherence to kidney disease: improving global outcomes 2012 CKD clinical practice guidelines despite clear evidence of utility. Kidney Int Rep. 2022;7(9):2059\u201370. https:\/\/doi.org\/10.1016\/j.ekir.2022.05.033.","journal-title":"Kidney Int Rep"},{"issue":"4","key":"3228_CR19","doi-asserted-by":"publisher","first-page":"S263","DOI":"10.1016\/j.ekir.2024.02.540","volume":"9","author":"AF Moura","year":"2024","unstructured":"Moura AF, Wheeler D, Brotons-Munto F, et al. WCN24-1204 multidimensional burden of chronic kidney disease in eight countries: insights from the impact CKD study. Kidney Int Rep. 2024;9(4):S263. https:\/\/doi.org\/10.1016\/j.ekir.2024.02.540.","journal-title":"Kidney Int Rep"},{"issue":"10","key":"3228_CR20","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1007\/s12325-023-02608-9","volume":"40","author":"V Jha","year":"2023","unstructured":"Jha V, Al-Ghamdi SMG, Li G, et al. Global economic burden associated with chronic kidney disease: a pragmatic review of medical costs for the inside CKD research programme. Adv Ther. 2023;40(10):4405\u201320. https:\/\/doi.org\/10.1007\/s12325-023-02608-9.","journal-title":"Adv Ther"},{"issue":"3","key":"3228_CR21","doi-asserted-by":"publisher","first-page":"352","DOI":"10.34067\/KID.0000000000000374","volume":"5","author":"N Tangri","year":"2024","unstructured":"Tangri N, Svensson MK, Bodegard J, et al. Mortality, health care burden, and treatment of CKD: a multinational, observational study (OPTIMISE-CKD). Kidney360. 2024;5(3):352\u201362. https:\/\/doi.org\/10.34067\/KID.0000000000000374.","journal-title":"Kidney360"},{"issue":"7","key":"3228_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765. https:\/\/doi.org\/10.1371\/journal.pone.0158765.","journal-title":"PLoS One"},{"issue":"1","key":"3228_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.kint.2020.10.012","volume":"99","author":"MG Shlipak","year":"2021","unstructured":"Shlipak MG, Tummalapalli SL, Boulware LE, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 2021;99(1):34\u201347. https:\/\/doi.org\/10.1016\/j.kint.2020.10.012.","journal-title":"Kidney Int"},{"issue":"1","key":"3228_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s12325-020-01568-8","volume":"38","author":"M Murton","year":"2021","unstructured":"Murton M, Goff-Leggett D, Bobrowska A, et al. Burden of chronic kidney disease by KDIGO categories of glomerular filtration rate and albuminuria: a systematic review. Adv Ther. 2021;38(1):180\u2013200. https:\/\/doi.org\/10.1007\/s12325-020-01568-8.","journal-title":"Adv Ther"},{"issue":"1","key":"3228_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12325-021-02006-z","volume":"39","author":"JJ Garcia Sanchez","year":"2021","unstructured":"Garcia Sanchez JJ, Thompson J, Scott DA, et al. Treatments for chronic kidney disease: a systematic literature review of randomized controlled trials. Adv Ther. 2021;39(1):193\u2013220. https:\/\/doi.org\/10.1007\/s12325-021-02006-z.","journal-title":"Adv Ther"},{"issue":"1","key":"3228_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.kisu.2016.01.004","volume":"6","author":"M Epstein","year":"2016","unstructured":"Epstein M. Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena. Kidney Int Suppl. 2016;6(1):20\u20138. https:\/\/doi.org\/10.1016\/j.kisu.2016.01.004.","journal-title":"Kidney Int Suppl"},{"issue":"11 Suppl","key":"3228_CR27","first-page":"S212","volume":"21","author":"M Epstein","year":"2015","unstructured":"Epstein M, Reaven NL, Funk SE, et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(11 Suppl):S212\u201320.","journal-title":"Am J Manag Care"},{"key":"3228_CR28","doi-asserted-by":"publisher","first-page":"100438","DOI":"10.1016\/j.lanepe.2022.100438","volume":"20","author":"J Sundstr\u00f6m","year":"2022","unstructured":"Sundstr\u00f6m J, Bodegard J, Bollmann A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2.4\u00a0million patients from 11 countries: the CaReMe CKD study. Lancet Reg Health Eur. 2022;20:100438. https:\/\/doi.org\/10.1016\/j.lanepe.2022.100438.","journal-title":"Lancet Reg Health Eur"},{"issue":"22","key":"3228_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012655","volume":"8","author":"C Linde","year":"2019","unstructured":"Linde C, Bakhai A, Furuland H, et al. Real-world associations of renin-angiotensin-aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom. J Am Heart Assoc. 2019;8(22):e012655. https:\/\/doi.org\/10.1161\/JAHA.119.012655.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"3228_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12882-022-03054-5","volume":"24","author":"E Kanda","year":"2023","unstructured":"Kanda E, Rastogi A, Murohara T, et al. Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia. BMC Nephrol. 2023;24(1):18. https:\/\/doi.org\/10.1186\/s12882-022-03054-5.","journal-title":"BMC Nephrol"},{"issue":"3","key":"3228_CR31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/jamainternmed.2013.12700","volume":"174","author":"TW Hsu","year":"2014","unstructured":"Hsu TW, Liu JS, Hung SC, et al. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. JAMA Intern Med. 2014;174(3):347\u201354. https:\/\/doi.org\/10.1001\/jamainternmed.2013.12700.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"3228_CR32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2215\/cjn.12950921","volume":"17","author":"TI Chang","year":"2022","unstructured":"Chang TI, Lerma EV. Optimizing renin-angiotensin system inhibitor use in CKD. Clin J Am Soc Nephrol. 2022;17(1):131\u20133. https:\/\/doi.org\/10.2215\/cjn.12950921.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3228_CR33","doi-asserted-by":"publisher","first-page":"215013192412599","DOI":"10.1177\/21501319241259905","volume":"15","author":"A Rastogi","year":"2024","unstructured":"Rastogi A, Collins A, Kelepouris E, et al. Practical considerations and implementation of sodium-glucose co-transporter-2 inhibitors in chronic kidney disease: who, when, and how? A position statement by nephrologists. J Prim Care Community Health. 2024;15:21501319241259904. https:\/\/doi.org\/10.1177\/21501319241259905.","journal-title":"J Prim Care Community Health"},{"issue":"24","key":"3228_CR34","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type\u00a02 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"issue":"15","key":"3228_CR35","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"1","key":"3228_CR36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.7326\/m22-2115","volume":"176","author":"M Schechter","year":"2023","unstructured":"Schechter M, Jongs N, Chertow GM, et al. Effects of dapagliflozin on hospitalizations in patients with chronic kidney disease: a post hoc analysis of DAPA-CKD. Ann Intern Med. 2023;176(1):59\u201366. https:\/\/doi.org\/10.7326\/m22-2115.","journal-title":"Ann Intern Med"},{"issue":"2","key":"3228_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"},{"key":"3228_CR38","doi-asserted-by":"publisher","first-page":"205435811984812","DOI":"10.1177\/2054358119848126","volume":"6","author":"S Baay","year":"2019","unstructured":"Baay S, Hemmelgarn B, Tam-Tham H, et al. Understanding adults with chronic kidney disease and their caregivers\u2019 self-management experiences: a qualitative study using the theoretical domains framework. Can J Kidney Health Dis. 2019;6:2054358119848126. https:\/\/doi.org\/10.1177\/2054358119848126.","journal-title":"Can J Kidney Health Dis"},{"issue":"10365","key":"3228_CR39","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/s0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788\u2013801. https:\/\/doi.org\/10.1016\/s0140-6736(22)02074-8.","journal-title":"Lancet"},{"issue":"1","key":"3228_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/s2213-8587(23)00355-8","volume":"12","author":"C Zoccali","year":"2024","unstructured":"Zoccali C, Mallamaci F. Empagliflozin in chronic kidney disease: nephroprotection is independent of albuminuria, primary kidney disease, and baseline eGFR. Lancet Diabetes Endocrinol. 2024;12(1):5\u20138. https:\/\/doi.org\/10.1016\/s2213-8587(23)00355-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"3228_CR41","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s12325-023-02773-x","volume":"41","author":"N Tangri","year":"2024","unstructured":"Tangri N, Rastogi A, Nekeman-Nan C, et al. Dapagliflozin utilization in chronic kidney disease and its real-world effectiveness among patients with lower levels of albuminuria in the USA and Japan. Adv Ther. 2024;41(3):1151\u201367. https:\/\/doi.org\/10.1007\/s12325-023-02773-x.","journal-title":"Adv Ther"},{"issue":"8","key":"3228_CR42","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/ckj\/sfae100","volume":"17","author":"MK Svensson","year":"2024","unstructured":"Svensson MK, Tangri N, Bodeg\u00e5rd J, et al. Dapagliflozin treatment of patients with chronic kidney disease without diabetes across different albuminuria levels (OPTIMISE-CKD). Clin Kidney J. 2024;17(8):100. https:\/\/doi.org\/10.1093\/ckj\/sfae100.","journal-title":"Clin Kidney J"},{"key":"3228_CR43","doi-asserted-by":"publisher","first-page":"1031306","DOI":"10.3389\/fpubh.2022.1031306","volume":"10","author":"GB Korayem","year":"2022","unstructured":"Korayem GB, Alshaya OA, Alghamdi AA, et al. The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: a two-center retrospective cross-sectional study. Front Public Health. 2022;10:1031306. https:\/\/doi.org\/10.3389\/fpubh.2022.1031306.","journal-title":"Front Public Health"},{"issue":"3","key":"3228_CR44","doi-asserted-by":"publisher","first-page":"455","DOI":"10.34067\/kid.0007862021","volume":"3","author":"M Zhuo","year":"2022","unstructured":"Zhuo M, Li J, Buckley LF, et al. Prescribing patterns of sodium-glucose cotransporter-2 inhibitors in patients with CKD: a cross-sectional registry analysis. Kidney360. 2022;3(3):455\u201364. https:\/\/doi.org\/10.34067\/kid.0007862021.","journal-title":"Kidney360"},{"issue":"23","key":"3228_CR45","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type\u00a02 diabetes. N Engl J Med. 2020;383(23):2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845.","journal-title":"N Engl J Med"},{"issue":"24","key":"3228_CR46","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type\u00a02 diabetes. N Engl J Med. 2021;385(24):2252\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2110956.","journal-title":"N Engl J Med"},{"issue":"10","key":"3228_CR47","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type\u00a02 diabetes. N Engl J Med. 2021;385(10):896\u2013907. https:\/\/doi.org\/10.1056\/NEJMoa2108269.","journal-title":"N Engl J Med"},{"issue":"10157","key":"3228_CR48","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/s0140-6736(18)32261-x","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type\u00a02 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329. https:\/\/doi.org\/10.1016\/s0140-6736(18)32261-x.","journal-title":"Lancet"},{"issue":"4","key":"3228_CR49","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type\u00a02 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"19","key":"3228_CR50","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type\u00a02 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"10","key":"3228_CR51","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/s2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type\u00a02 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776\u201385. https:\/\/doi.org\/10.1016\/s2213-8587(19)30249-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"3228_CR52","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/s2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type\u00a02 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653\u201362. https:\/\/doi.org\/10.1016\/s2213-8587(21)00203-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"3228_CR53","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type\u00a02 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"issue":"9","key":"3228_CR54","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","volume":"38","author":"P Rossing","year":"2023","unstructured":"Rossing P, Baeres FMM, Bakris G, et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type\u00a02 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023;38(9):2041\u201351. https:\/\/doi.org\/10.1093\/ndt\/gfad009.","journal-title":"Nephrol Dial Transplant"},{"key":"3228_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105835","volume":"172","author":"GL Hundemer","year":"2021","unstructured":"Hundemer GL, Sood MM. Hyperkalemia with RAAS inhibition: mechanism, clinical significance, and management. Pharmacol Res. 2021;172:105835. https:\/\/doi.org\/10.1016\/j.phrs.2021.105835.","journal-title":"Pharmacol Res"},{"key":"3228_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.653634","volume":"8","author":"E Morales","year":"2021","unstructured":"Morales E, Cravedi P, Manrique J. Management of chronic hyperkalemia in patients with chronic kidney disease: an old problem with new options. Front Med (Lausanne). 2021;8:653634. https:\/\/doi.org\/10.3389\/fmed.2021.653634.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"3228_CR57","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2215\/CJN.07821109","volume":"5","author":"MR Weir","year":"2010","unstructured":"Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5(3):531\u201348. https:\/\/doi.org\/10.2215\/CJN.07821109.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"3228_CR58","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1093\/ndt\/gfae016","volume":"39","author":"MK Svensson","year":"2024","unstructured":"Svensson MK, Murohara T, Les\u00e9n E, et al. Hyperkalaemia-related reduction of RAASi treatment associates with more subsequent inpatient care. Nephrol Dial Transplant. 2024;39(8):1258\u201367. https:\/\/doi.org\/10.1093\/ndt\/gfae016.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"3228_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173542","volume":"12","author":"MY Yu","year":"2017","unstructured":"Yu MY, Yeo JH, Park JS, Lee CH, Kim GH. Long-term efficacy of oral calcium polystyrene sulfonate for hyperkalemia in CKD patients. PLoS One. 2017;12(3):e0173542. https:\/\/doi.org\/10.1371\/journal.pone.0173542.","journal-title":"PLoS One"},{"key":"3228_CR60","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.2147\/DDDT.S143461","volume":"11","author":"V Zann","year":"2017","unstructured":"Zann V, McDermott J, Jacobs JW, et al. Palatability and physical properties of potassium-binding resin RDX7675: comparison with sodium polystyrene sulfonate. Drug Des Devel Ther. 2017;11:2663\u201373. https:\/\/doi.org\/10.2147\/DDDT.S143461.","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"3228_CR61","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamainternmed.2019.0631","volume":"179","author":"JA Noel","year":"2019","unstructured":"Noel JA, Bota SE, Petrcich W, et al. Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age. JAMA Intern Med. 2019;179(8):1025\u201333. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0631.","journal-title":"JAMA Intern Med"},{"issue":"9","key":"3228_CR62","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1093\/ndt\/gfz150","volume":"35","author":"P Laureati","year":"2020","unstructured":"Laureati P, Xu Y, Trevisan M, et al. Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study. Nephrol Dial Transplant. 2020;35(9):1518\u201326. https:\/\/doi.org\/10.1093\/ndt\/gfz150.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"3228_CR63","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-074954","volume":"14","author":"DC Wheeler","year":"2024","unstructured":"Wheeler DC, Sondergaard H, Gwynn C, et al. Randomised, blinded, cross-over evaluation of the palatability of and preference for different potassium binders in participants with chronic hyperkalaemia in the USA, Canada and Europe: the APPETIZE study. BMJ Open. 2024;14(2):e074954. https:\/\/doi.org\/10.1136\/bmjopen-2023-074954.","journal-title":"BMJ Open"},{"issue":"11","key":"3228_CR64","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1093\/ckj\/sfab076","volume":"14","author":"AO de Labry Lima","year":"2021","unstructured":"de Labry Lima AO, Castro \u00d3D, Romero-Requena JR, et al. Hyperkalaemia management and related costs in chronic kidney disease patients with comorbidities in Spain. Clin Kidney J. 2021;14(11):2391\u2013400. https:\/\/doi.org\/10.1093\/ckj\/sfab076.","journal-title":"Clin Kidney J"},{"issue":"6","key":"3228_CR65","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1159\/000504078","volume":"50","author":"SD Roger","year":"2019","unstructured":"Roger SD, Spinowitz BS, Lerma EV, et al. Efficacy and safety of sodium zirconium cyclosilicate for treatment of hyperkalemia: an 11-month open-label extension of HARMONIZE. Am J Nephrol. 2019;50(6):473\u201380. https:\/\/doi.org\/10.1159\/000504078.","journal-title":"Am J Nephrol"},{"issue":"1","key":"3228_CR66","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/ehf2.12561","volume":"7","author":"F Zannad","year":"2020","unstructured":"Zannad F, Hsu BG, Maeda Y, et al. Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study. ESC Heart Fail. 2020;7(1):54\u201364. https:\/\/doi.org\/10.1002\/ehf2.12561.","journal-title":"ESC Heart Fail"},{"issue":"3","key":"3228_CR67","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"MR Weir","year":"2015","unstructured":"Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372(3):211\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1410853.","journal-title":"N Engl J Med"},{"issue":"9","key":"3228_CR68","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ekir.2019.05.018","volume":"4","author":"N Kashihara","year":"2019","unstructured":"Kashihara N, Kohsaka S, Kanda E, Okami S, Yajima T. Hyperkalemia in real-world patients under continuous medical care in Japan. Kidney Int Rep. 2019;4(9):1248\u201360. https:\/\/doi.org\/10.1016\/j.ekir.2019.05.018.","journal-title":"Kidney Int Rep"},{"issue":"18","key":"3228_CR69","doi-asserted-by":"publisher","first-page":"5330","DOI":"10.3390\/jcm11185330","volume":"11","author":"T Imamura","year":"2022","unstructured":"Imamura T, Narang N, Kinugawa K. Impact of sodium zirconium cyclosilicate therapy cessation in patients with systolic heart failure. J Clin Med. 2022;11(18):5330. https:\/\/doi.org\/10.3390\/jcm11185330.","journal-title":"J Clin Med"},{"issue":"23","key":"3228_CR70","doi-asserted-by":"publisher","first-page":"7096","DOI":"10.3390\/jcm11237096","volume":"11","author":"T Imamura","year":"2022","unstructured":"Imamura T, Narang N, Kinugawa K. Risk factors for rapid recurrence of hyperkalemia following cessation of sodium zirconium cyclosilicate. J Clin Med. 2022;11(23):7096. https:\/\/doi.org\/10.3390\/jcm11237096.","journal-title":"J Clin Med"},{"issue":"5","key":"3228_CR71","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/ndt\/gfu383","volume":"30","author":"L De Nicola","year":"2014","unstructured":"De Nicola L, Donfrancesco C, Minutolo R, et al. Prevalence and cardiovascular risk profile of chronic kidney disease in Italy: results of the 2008\u201312 National Health Examination Survey. Nephrol Dial Transplant. 2014;30(5):806\u201314. https:\/\/doi.org\/10.1093\/ndt\/gfu383.","journal-title":"Nephrol Dial Transplant"},{"key":"3228_CR72","unstructured":"International Society of Nephrology. ISN Global Kidney Health Atlas. 2023. https:\/\/www.theisn.org\/wp-content\/uploads\/media\/ISN%20Atlas_2023%20Digital_REV_2023_10_03.pdf. Accessed 19 Sept 2024"},{"issue":"5","key":"3228_CR73","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1053\/j.ajkd.2013.12.012","volume":"63","author":"P Komenda","year":"2014","unstructured":"Komenda P, Ferguson TW, Macdonald K, et al. Cost-effectiveness of primary screening for CKD: a systematic review. Am J Kidney Dis. 2014;63(5):789\u201397. https:\/\/doi.org\/10.1053\/j.ajkd.2013.12.012.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"3228_CR74","doi-asserted-by":"publisher","first-page":"788","DOI":"10.7326\/m22-3228","volume":"176","author":"MM Cusick","year":"2023","unstructured":"Cusick MM, Tisdale RL, Chertow GM, Owens DK, Goldhaber-Fiebert JD. Population-wide screening for chronic kidney disease: a cost-effectiveness analysis. Ann Intern Med. 2023;176(6):788\u201397. https:\/\/doi.org\/10.7326\/m22-3228.","journal-title":"Ann Intern Med"},{"key":"3228_CR75","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2147\/ceor.S470728","volume":"16","author":"F Pesce","year":"2024","unstructured":"Pesce F, Bruno GM, Colombo GL, et al. Clinical and economic impact of early diagnosis of chronic kidney disease in general practice: the endorse study. Clinicoecon Outcomes Res. 2024;16:547\u201355. https:\/\/doi.org\/10.2147\/ceor.S470728.","journal-title":"Clinicoecon Outcomes Res"},{"key":"3228_CR76","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2024nbfey7yh","author":"E Reinhardt","year":"2024","unstructured":"Reinhardt E, Peduzzi JN, Jaworsky N, Zuik J, El Fadawy N. A collaborative approach: pharmacist-led CKD clinic in the primary care setting: SA-PO1120. J Am Soc Nephrol. 2024. https:\/\/doi.org\/10.1681\/ASN.2024nbfey7yh.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"3228_CR77","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1111\/jch.14372","volume":"23","author":"H Li","year":"2021","unstructured":"Li H, Radhakrishnan J. A pharmacist-physician collaborative care model in chronic kidney disease. J Clin Hypertens (Greenwich). 2021;23(11):2026\u20139. https:\/\/doi.org\/10.1111\/jch.14372.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"11","key":"3228_CR78","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1093\/ckj\/sfac104","volume":"15","author":"N Oliva-Damaso","year":"2022","unstructured":"Oliva-Damaso N, Delanaye P, Oliva-Damaso E, Payan J, Glassock RJ. Risk-based versus GFR threshold criteria for nephrology referral in chronic kidney disease. Clin Kidney J. 2022;15(11):1996\u20132005. https:\/\/doi.org\/10.1093\/ckj\/sfac104.","journal-title":"Clin Kidney J"},{"key":"3228_CR79","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf049.10.1093\/ckj\/sfaf049","author":"RW Major","year":"2025","unstructured":"Major RW, Lakhani N, Ahmed Y, et al. Integrated primary and secondary care optimises the management of people with CKD - the LUCID project. Clin Kidney J. 2025. https:\/\/doi.org\/10.1093\/ckj\/sfaf049.10.1093\/ckj\/sfaf049.","journal-title":"Clin Kidney J"},{"issue":"9","key":"3228_CR80","doi-asserted-by":"publisher","first-page":"101131","DOI":"10.1016\/j.jacadv.2024.101131","volume":"3","author":"S Oskouie","year":"2024","unstructured":"Oskouie S, Pandey A, Sauer AJ, et al. From hospital to home: evidence-based care for worsening heart\u00a0failure. JACC Adv. 2024;3(9):101131. https:\/\/doi.org\/10.1016\/j.jacadv.2024.101131.","journal-title":"JACC Adv"},{"issue":"3","key":"3228_CR81","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.55816","volume":"16","author":"R Santosh","year":"2024","unstructured":"Santosh R, Mohammed YN, Rahaman Z, Khurana S. The role of telemedicine in enhancing chronic kidney disease (CKD) management and dialysis care. Cureus. 2024;16(3):e55816. https:\/\/doi.org\/10.7759\/cureus.55816.","journal-title":"Cureus"},{"issue":"1","key":"3228_CR82","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.hlpt.2020.10.006","volume":"10","author":"CS Kruse","year":"2021","unstructured":"Kruse CS, Williams K, Bohls J, Shamsi W. Telemedicine and health policy: a systematic review. Health Policy Technol. 2021;10(1):209\u201329. https:\/\/doi.org\/10.1016\/j.hlpt.2020.10.006.","journal-title":"Health Policy Technol"},{"issue":"11","key":"3228_CR83","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1681\/asn.2022030306","volume":"33","author":"N Jongs","year":"2022","unstructured":"Jongs N, Chertow GM, Greene T, et al. Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with CKD. J Am Soc Nephrol. 2022;33(11):2094\u2013107. https:\/\/doi.org\/10.1681\/asn.2022030306.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"3228_CR84","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.xkme.2021.03.009","volume":"3","author":"JA Green","year":"2021","unstructured":"Green JA, Ephraim PL, Hill-Briggs F, et al. Integrated digital health system tools to support decision making and treatment preparation in CKD: the PREPARE NOW study. Kidney Med. 2021;3(4):565-75.e1. https:\/\/doi.org\/10.1016\/j.xkme.2021.03.009.","journal-title":"Kidney Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03228-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03228-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03228-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:14:45Z","timestamp":1750479285000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03228-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":84,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3228"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03228-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Christoph Wanner reports receiving honoraria for steering committee and advisory board participation, and lecturing from Alexion, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Vifor, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, and Sanofi. Ming-Hui Zhao reports receiving honoraria for advisory boards and consulting fees from AstraZeneca, BeiGene, Kira, Novartis, Roche, and SanReno. Alpesh N. Amin was principal investigator or co-investigator of clinical trials sponsored by Alexion, Aseptiscope, Blade Therapeutics, Eli Lilly, Fulcrum Therapeutics, Humanigen, NeuroRx Pharma, National Institutes of Health\/National Institute of Allergy and Infectious Diseases, Novartis, OctaPharma, PTC Therapeutics, Pulmotect, and Takeda; and speaker and\/or consultant for Alexion, AstraZeneca, Bayer, Dexcom, Eli Lilly, Ferring, Gilead, GSK, HeartRite, Novo Nordisk, Pfizer, Renibus, Reprieve, Salix, Seres, and Spero (unrelated to this manuscript). Luca De Nicola reports receiving honoraria for participation on advisory boards and lectures from Astellas, AstraZeneca, Bayer, and Novo Nordisk. Andrew J. Sauer reports receiving research funding support from AstraZeneca, Bayer, Boehringer Ingelheim, CSL Vifor, Edwards Lifesciences, Heart Failure Society of America, Novo Nordisk, Pfizer, 35Pharma, Rivus Pharmaceuticals, and Story Health; consultancy fees from Abbott, Acorai, Amgen, Bayer, Boston Scientific, Edwards Lifesciences, General Prognostics, Impulse Dynamics, and Story Health; and stock ownership in ISHI and Pulsli (privately held digital health companies). Alaster M. Allum, Unai Aranda, and You-Seon Nam are employees of, and may hold stock and\/or stock options in, AstraZeneca. Javed Butler reports receiving consultancy fees from Abbott, American Regent, Amgen, Applied Therapeutic, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardior, CSL Bering, CVRx, Cytokinetics, Edwards Lifesciences, Element Science, Faraday, Foundry, Innolife, Impulse Dynamics, Imbria, Inventiva, Ionis, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Regeneron, Renibus, Roche, Salamandra, Sanofi, SC Pharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vifor, and Zoll.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals that were performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}